V-9302
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


V-9302
UNSPSC Description:
V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC50=9.6 μM) in HEK-293 cells[1].Target Antigen:
ASCTType:
Reference compoundRelated Pathways:
Membrane Transporter/Ion ChannelApplications:
Cancer-programmed cell deathField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/v-9302.htmlPurity:
99.88Solubility:
DMSO : 25 mg/mL (ultrasonic;warming;heat to 80°C)|H2O : < 0.1 mg/mL (ultrasonic)Smiles:
O=C(O)[C@@H](N)CCN(CC1=CC=CC=C1OCC2=CC=CC(C)=C2)CC3=CC=CC=C3OCC4=CC=CC(C)=C4Molecular Weight:
538.68References & Citations:
[1]Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24(2):194-202.|[2]Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5.|[3]Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100.bioRxiv. 2024 July 05.|Cell Death Dis. 2024 Feb 5;15(2):111.|Cell Metab. 2022 Nov 11;S1550-4131(22)00490-9.|Cell. 2024 Oct 31;187(22):6251-6271.e20.|Front Pharmacol. 2021 May 14;12:671328.|J Biol Chem. 2022 Feb 18;101753.|J Control Release. 2023 Apr 19;357:460-471.|Magn Reson Imaging. 2022 Aug 24;S0730-725X(22)00149-7.|Nat Immunol. 2024 Aug 28.|Pharmaceutics. 2024 Jun 29.|Proc Natl Acad Sci U S A. 2024 Mar 26;121(13):e2319429121.|University of Regensburg. 2024 Jul 18.|J Nanobiotechnology. 2022 May 6;20(1):216.|Research Square Print. 2023 Jan 31.Shipping Conditions:
Room TemperatureStorage Conditions:
4°C (Powder, sealed storage, away from moisture)Clinical Information:
No Development ReportedCAS Number:
1855871-76-9
